Valuation: LadRx Corporation

Market Cap 5.45T 4.88T 4.49T 4.07T 7.6T 5L 7.74T 53.5T 21.48T 3L 20.44T 20T 9L P/E 2023
1.91x
P/E 2024 -0.52x
Enterprise Value -8L -7L -6L -6L -10.52L -7.16Cr -10.72L -74.1L -29.75L -3.77Cr -28.31L -27.71L -12Cr EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99.32%
Yield 2023 *
-
Yield 2024 -
1 day+10,99,900.00%
1 week+10,99,900.00%
1 month+10,99,900.00%
6 months-89.52%
1 month 0
Extreme 1.0E-6
0.01
Current year 0
Extreme 1.0E-6
0.11
1 year 0
Extreme 1.0E-6
0.2
3 years 0
Extreme 1.0E-6
3.5
5 years 0
Extreme 1.0E-6
86
10 years 0
Extreme 1.0E-6
598.8
Date Insider Type Main position Quantity % Market Cap. Importance
15/01/24 Free

Director

5,000 1.0099%
15/01/24 Free

Chairman

5,000 1.0099%
15/01/24 Free

Director

5,000 1.0099%
Change 5-day change 1-year change 3-year change Capi.($)
+10,99,900.00%+10,99,900.00%-98.53%-99.12% 5.45T
-0.62%-1.87%+42.87%+67.17% 6.38TCr
-0.72%+2.72%+12.91%+72.94% 5.64TCr
+0.59%+1.42%+19.40%+101.19% 5.46TCr
-2.81%-4.31%+23.50%+48.51% 4.41TCr
-0.33%-1.93%+19.28%+104.26% 4.21TCr
+0.55%+2.31%+225.14%+840.10% 4.1TCr
-1.67%+30.16%+106.92%+95.44% 3.49TCr
+1.22%-1.44%+14.57%+47.05% 3.28TCr
+0.89%+20.55%-40.62%+350.50% 2.47TCr
Average +1,09,989.71%+6.79%+32.54%+162.80% 3.94TCr
Weighted average by Cap. -0.39%+5.44%+47.69%+173.53%

Financials

2023 2024
Net sales - -
Net income 4L 4L 3L 3L 6L 3.8Cr 6L 39.34L 15.79L 2Cr 15.03L 14.71L 6.31Cr -15.9L -14.24L -13.1L -11.87L -22.18L -15Cr -22.6L -1.56Cr -62.69L -7.94Cr -59.66L -58.39L -25Cr
Net Debt -20.36L -18.24L -16.78L -15.2L -28.41L -19Cr -28.95L -2Cr -80.31L -10Cr -76.43L -74.8L -32Cr -8L -7L -6L -6L -10.6L -7.21Cr -10.8L -74.64L -29.96L -3.79Cr -28.51L -27.91L -12Cr
Projected Income Statement - Annual - LadRx Corporation
Logo LadRx Corporation
LadRx Corp is a biopharmaceutical research and development company specializing in oncology. The Company focuses on the discovery, research and clinical development of anti-cancer drug candidates that employ technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. The Company’s linker activated drug release (LADR) technology platform consists of an organic backbone that is attached to a chemo toxic agent. The LADR backbone is to first target and deliver the chemo toxic agent to the tumor environment, and then to release the chemo toxic agent within the tumor. The LADR Technology offers the opportunity for multiple pipeline drugs. The LADR development efforts are focused on two classes of ultra-high potency albumin-binding drugs. These LADR-based drugs, LADRs 7, 8, 9, and 10, combine the proprietary LADR backbone with derivatives of the auristatin and maytansinoid drug classes.
Employees
2
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. LADX Stock